1. Home
  2. GLU vs GNLX Comparison

GLU vs GNLX Comparison

Compare GLU & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Global Utility of Beneficial Ownership

GLU

Gabelli Global Utility of Beneficial Ownership

HOLD

Current Price

$19.31

Market Cap

116.8M

Sector

Finance

ML Signal

HOLD

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$3.46

Market Cap

202.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLU
GNLX
Founded
2004
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.8M
202.4M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
GLU
GNLX
Price
$19.31
$3.46
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.75
AVG Volume (30 Days)
12.4K
124.4K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
8.60%
N/A
EPS Growth
N/A
N/A
EPS
0.62
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.61
$1.99
52 Week High
$15.40
$8.54

Technical Indicators

Market Signals
Indicator
GLU
GNLX
Relative Strength Index (RSI) 60.65 28.22
Support Level $19.07 $4.21
Resistance Level $20.13 $4.99
Average True Range (ATR) 0.32 0.34
MACD 0.00 -0.02
Stochastic Oscillator 57.48 7.79

Price Performance

Historical Comparison
GLU
GNLX

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Share on Social Networks: